Revive Therapeutics Ltd C.RVV

FDA Expanded Access Program

[mrnormal]

What this means is that after early positive analysis during the Phase 3 trial, done by Advarra, a premier IRB services company in North America, Revive and the FDA will allow Bucillamine to market for licensed physicians in the US so that they DO NOT have to wait for the full study to be complete. Which means that Bucillamine should start helping save lives as early as mid-September!

Also note: Revive expects to have Covid use patients enrolled in September 2020.

Quote:

---

Study of Bucillamine...will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days.

[PowerofNow]

WELL SAID. Yes, mid-sept is my guess as well.

[Casperin]

happy Halloween everybody October rocks ?boooooooo

[GajjarDr]

it is well known among elite

[PowerofNow]

Here we go talking FACTS not CHIRP  https://www.fda.gov/medical-devices/investigational-device-exemption-ide/expanded-access-medical-devices

[pinkfloyd90]

please...go to bed...your an embarrassment to everyone.

[1ottrunner]

Zero point zero chance. The device does not meet the requirements Gentlemen you're a narcissist or a moron if you think posting this bs here helps move this stock up.

[pinkfloyd90]

yep....totally agree...cmon Michael...lets get some substantial NR or the stock price will drop and drop and drop....where is that energizer battery....oink oink oink